

HSBC Healthcare Day



Frankfurt, 23 November 2017

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

A Global Leader In HealthCare Products And Services



~€29.5 bn in Sales

(as of Dec. 31, 2016)

Strong portfolio of products (30% of sales) and services (70% of sales) Total Shareholder Return: 10-year CAGR: ~17% Global presence in 100+ countries

270,000+ employees worldwide (as of September 30, 2017)

FRESENIUS

Strong, Diversified Product And Service Portfolio











Ownership: 31%



Ownership: 100%




Ownership: 100%



Ownership: 77%


Dialysis Products Healthcare Services	Hospital Supplies and Services	Hospital Operations	Hospital Projects and Services
Sales 2016: €16.6 bn	Sales 2016: €6.0 bn	Sales 2016: €5.8 bn	Sales 2016: €1.2 bn
		Sales 2016 pro-forma Quirónsalud: ~€8.4 bn	

Total Shareholder Return – CAGR, rounded




Source: Bloomberg; dividends reinvested


Fresenius Group Consistent Cash Generation And Proven Track Record of Deleveraging




Capex gross, in % of sales



FCF margin (before acquisitions & dividends)



Net Debt / EBITDA¹



¹ At actual FX rates for both Net Debt and EBITDA; pro Forma acquisitions, before acquisition-related expenses

Fresenius Medical Care: Global Dialysis Market Leader

- The world's leading provider of dialysis products and services treating 317,792 patients¹ in 3,714 clinics¹
- Provide highest standard of product quality and patient care

မြဲ Dialysis products

Dialysis services



• Expansion in Care Coordination and global dialysis service opportunities; enter new geographies

Market Dynamics

Global Dialysis Market 2016:

- ~US\$76 bn
- ~6% patient growth p.a.

Growth Drivers:


 Aging population, increasing incidence of diabetes and high blood pressure, treatment quality improvements



¹ As of September 30, 2017

Fresenius Kabi: A Leading Global Hospital Supplier

- Comprehensive product portfolio for critically and chronically ill patients
- Strong Emerging Markets presence
- Leading market positions in four product segments



 Focus on organic growth through geographic product rollouts and new product launches


Market Dynamics

Global Addressable Market 2016:

• >€48 bn


Growth Drivers:

 Patent expirations, rising demand for health care services, higher health care spending in Emerging Markets



Fresenius Helios: Europe's largest private hospital operator Helios Kliniken Germany

- ~6% share in German acute care hospital market
- Solid organic growth based on growing number of admissions and reimbursement rate increases
- Strong track record in hospital acquisitions and operation
- Ranks as quality leader in the German hospital sector: defined quality targets, publication of medical treatment results, peer review processes
- Key medical indicators, e.g. mortality rate for heart failure, pneumonia below German average



¹ German Federal Statistical Office 2016; total costs, gross of the German hospitals less academic research and teaching

Market Dynamics

German Acute Care Hospital Market:

• ~€94 bn¹

Growth Drivers:

• Aging population leading to increasing hospital admissions, intermittent selective market consolidation, focus on larger entities, growing transparency of medical quality

Largest network & nationwide presence



111 hospitals

- ~35,000 beds
- ~1.3 million inpatient admissions p.a.
- ~3.9 million outpatient admissions p.a.

As of October 31, 2017

Fresenius Helios: Europe's largest private hospital operator Quirónsalud Spain

- ~€2.5bn sales in 2016
- ~10% share in Spanish private hospital market
- Market leader in size and quality with excellent growth prospects
- Broad revenue base with privately insured patients, PPPs, self-pay and Occupational Risk Prevention (ORP)
- Strong management team with proven track record
- Cross-selling opportunities

Acute Care

Outpatient

Occupational Risk Prevention

¹ Market data based on company research. Market definition does neither include Public Private Partnerships (PPP) nor Occupational Risk Prevention centers (ORP).

Market Dynamics

Spanish Private Hospital Market:

• ~€13 bn¹

Growth Drivers:

• Aging population, increasing number of privately insured patients, greenfield projects, market consolidation

Quirónsalud hospitals in every major metropolitan region of Spain



Fresenius Vamed: Leading Global hospital Projects And Services Specialist

 Manages hospital construction/expansion projects (51% of sales) and provides services (49% of sales) for health care facilities worldwide

Projects

Services

- Offers project development, planning, turnkey construction, maintenance as well as technical management, and total operational management
- Strong track record: More than 800 projects in 79 countries completed

Market Dynamics

Growth Drivers:

- Emerging Market demand for building and developing hospital infrastructure
- Outsourcing of non-medical services from public to private operators



Fresenius Group: 2017 Financial Outlook by Business Segment

€m (except	otherwise stated)		FY/16 Base	FY/17e Previous	Q1-3/17 Actual	FY/17e New
5	FRESENIUS KABI	Sales growth (org)	6,007	5% – 7%	7%	
	NADI	EBIT growth (cc)	1,171	6% – 8% ¹	7%²	
	FRESENIUS HELIOS	Sales growth (org)	5,843 ³	3% – 5% ³	4% ³	
	IILLIUS	Sales (reported)	5,843 ³	~8.6bn ⁴	6.4bn	
		EBIT	683 ³	1,020–1,070 ⁵	769	
V	FRESENIUS VAMED	Sales growth (org)	1,160	5% – 10%	1%	
•	VAMED	EBIT growth	69	5% – 10%	3%	

¹ Before acquisition-related expenses of ~€50 million; before expected expenditures for further development of biosimilars business of ~€60 million

² Consistent with scope of original guidance: before acquisition-related expenses, before expenditures for further development of biosimilars business

³ Helios Kliniken Germany, excluding Quirónsalud

⁴ Thereof Quirónsalud (11 months consolidated): ~€2.5 billion

⁵ Thereof Quirónsalud (11 months consolidated): €300 to €320 million

For a detailed overview of adjustments please see the reconciliation tables on slides 28-29.

Fresenius Group: 2017 Financial Guidance

€m (except otherwise stated)		FY/16 Base	FY/17e Previous	Q1-3/17 Actual	FY/17e New
F FRESENIUS	Sales growth (cc)	29,471	15% – 17%	16%	
	Net income ¹ growth (cc)	1,560	19% – 21%²	20% ³	


¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA

² Before acquisition-related expenses of ~ \in 50 million; before expected expenditures for further development of biosimilars business of ~ \in 60 million

³ Consistent with scope of original guidance: before acquisition-related expenses, before expenditures for further development of biosimilars business

For a detailed overview of adjustments please see the reconciliation tables on slides 28-29.

Fresenius Group: Ambitious Mid-Term Targets



¹ Mid-point of the February 2017 sales guidance, adjusted for exchange rates as of February 2017

² Mid-point of the February 2017 net income guidance, adjusted for exchange rates as of February 2017

³ Calculated on the basis of the mid-point of the 2020 target range

At February 2017 exchange rates; excluding strategic acquisitions; at current IFRS rules

Financial Review Q3/2017


















Fresenius Group: Q3/17 Key Financials




All figures consistent with scope of original guidance: before acquisition-related expenses, before expenditures for further development of biosimilars business All growth rates in constant currency (cc)

Net income attributable to shareholders of Fresenius SE & Co. KGaA

For a detailed overview of adjustments please see the reconciliation tables on slides 28-29.

Fresenius Group: Q3/17 Business Segment Growth



¹ Growth rate consistent with scope of original guidance: before acquisition-related expenses, before expenditures for further development of biosimilars business

For a detailed overview of adjustments please see the reconciliation tables on slides 28-29.

Fresenius Kabi: Q3/17 Regional Highlights (1/2)

North America

- 7% organic sales growth
- 20 Kabi-marketed IV drugs currently designated in shortage (vs. 17 at Q2/17)
- 6 product launches YTD; confirm 10+ target
- Confirm FY/17 outlook: Mid-single-digit organic sales growth





Europe

- 4% organic sales growth
- Positive development in virtually all product segments
- Confirm FY/17 outlook: Low to mid-single-digit organic sales growth



FRESENIUS

Fresenius Kabi: Q3/17 Regional Highlights (2/2)

Emerging Markets

<u>China</u>

- 12% organic sales growth
- New tender rules:
 - 21 of 31 provinces have concluded a tender process; introduction of new tender policy now expected to be completed early 2018
 - Expectation for FY/17 unchanged low to mid single-digit price impact and continued double-digit volume growth

<u>Asia-Pacific ex China:</u> 12% organic sales growth

Latin America/Africa: 8% organic sales growth



Total Emerging Markets

Confirm FY/17 outlook: at least 10% organic sales growth



Fresenius Kabi: Organic Sales Growth by Product Segment

€m	Q3/17	Δ YoY organic	Q1-3/17	Δ YoY organic
IV Drugs	648	9%	2,030	8%
Infusion Therapy	221	4%	676	6%
Clinical Nutrition	427	10%	1,254	9%
Medical Devices/ Transfusion Technology	266	0%	804	3%
Total sales	1,562	7%	4,764	7%

Fresenius Kabi: Organic Sales Growth by Regions

€m	Q3/17	Δ YoY organic	Q1-3/17	Δ YoY organic
Europe	538	4%	1,635	5%
North America	549	7%	1,736	6%
Asia-Pacific/Latin America/Africa	475	10%	1,393	10%
Asia-Pacific	312	12%	894	11%
Latin America/Africa	163	8%	499	10%
Total sales	1,562	7%	4,764	7%

Fresenius Kabi: Q3 & Q1-3/17 EBIT Growth

€m	Q3/17	Δ YoY cc	Q1-3/17	Δ YoY cc
North America	203	3%	659	4%
Margin	37.0%	-170 bps	38.0%	-100 bps
Europe	80	5%	244	3%
Margin	14.9%	10 bps	14.9%	-20 bps
Asia-Pacific/Latin America/Africa ^{Margin}	100 21.1%	11% 10 bps	272 19.5%	13% 10 bps
Corporate and Corporate R&D	-100	-4%	-270	-5%
Total EBIT¹	283	6%	905	6%
Margin ¹	18.1%	-50 bps	19.0%	-40 bps
Total adjusted EBIT²	297	11%	919	7%
Margin ²	19.0%	40 bps	19.3%	-10 bps

Margin growth at actual rates

¹ Before acquisition-related expenses

² Consistent with scope of original guidance: before acquisition-related expenses, before expenditures for further development of biosimilars business

For a detailed overview of special items please see the reconciliation tables on slides 28-29.


Fresenius Helios: Q3 & Q1-Q3/17 Highlights

Helios Kliniken

- n 📕
- Organic growth in line with expectations
- Ongoing favorable reimbursement environment: 2018 DRG inflator set at 2.97%
- Roll-out of new brand image
 Helios

Quirónsalud

- Soft summer quarter as expected
- Solid YoY growth:
 - 10% sales growth in Q1-Q3/17
 - EBIT growth exceeds sales growth





Fresenius Helios: Q3 & Q1-3/17 Key Financials

€m	Q3/17	Δ ΥοΥ	Q1-3/17	Δ ΥοΥ
Total sales	2,166	47%	6,422	47%
Thereof Helios Kliniken	1,524	4%	4,562	4%
Thereof Quirónsalud ¹	642		1,860	
Total EBIT Margin	232 10.7%	33% -120 bps	769 12.0%	52% 40 bps
Thereof Helios Kliniken Margin	190 12.5%	9% 60 bps	549 12.0%	8% 40 bps
Thereof Quirónsalud ¹ Margin	42 6.5%		220 11.8%	

¹ Consolidated since 1 February 2017

Fresenius Vamed: Q3 & Q1-Q3/17 Highlights

- 1% organic sales growth YTD reflects typical quarterly fluctuations of project business
- Continued strong order intake; new projects in Germany, Zambia and Equatorial Guinea
- Two acquisitions to strengthen service business



€m	Q3/17	Δ ΥοΥ	Q1-3/17	Δ ΥοΥ
Project business	117	-10%	301	-7%
Service business	150	9%	447	8%
Total sales	267	0%	748	1%
Total EBIT	15	0%	32	3%
Order intake ¹	285	36%	697	3%
Order backlog ¹			2,345	20% ²

¹ Project business only ² Versus December 31, 2016

Fresenius Group: Q3/17 & LTM Cash Flow

	Operat	ing CF	Capex	Capex (net)		sh Flow ¹
€m	Q3/17	LTM Margin	Q3/17	LTM Margin	Q3/17	LTM Margin
	245 ²	15.6% ²	-96	-6.0%	149	9.6%
FRESENIUS HELIOS	256	9.5%	-102	-5.1%	154	4.4% ³
	35	1.0%	-3	-0.6%	32	0.4%
Corporate/Other	-10	n.a.	-4	n.a.	-14	n.a.
FRESENIUS Excl. FMC	526	11.7% ⁴	-205	-5.2%	321	6 .5% ⁴
	1,138	12.5%	-431	-5.0%	707	7.5%

¹ Before acquisitions and dividends

² Including the cash prepayment of €45 million for biosimilars business (LTM: 16.3% operating cashflow margin excl. cash prepayment biosimilars)

³ Understated: 4.9% excluding €37 million of capex commitments from acquisitions

⁴ Margin incl. FMC dividend

€m	Q3/17	LTM Margin	Q3/16 l	TM Margin	Δ ΥοΥ
Operating Cash Flow	1,138	12.5 %	940	11.9%	21%
Capex (net)	-431	-5.0%	-383	-5.5%	-13%
Free Cash Flow (before acquisitions and dividends)	707	7.5%	557	6.4%	27%
Acquisitions (net)	-227		-40		
Dividends	-68		-58		
Free Cash Flow (after acquisitions and dividends)	412	-14.4%	459	3.0%	-10.0%

Reconciliation Q3/17

The table below shows the adjustments and the reconciliation from net income according to guidance, i.e. before acquisition-related expenses and before expenditures for further development of biosimilars business to net income according to IFRS.

03/17

		03/17			
€m	Before acquisition-related expenses and before expenditures for further development of biosimilars business	Expenditures for further development of biosimilars business	Before acquisition- related expenses	Acquisition- related expenses	IFRS reported
Sales	8,297		8,297		8,297
EBIT Net interest	1,143 -158	-14	1,129 -158	-15 -5	1,114 -163
Net income before taxes Income taxes	985 -270	-14 4	971 -266	-20 3	951 -263
Net income Noncontrolling interest	715 -292	-10	705 -292	-17	688 -292
Net income attributable to shareholders of Fresenius SE & Co. KGaA	423	-10	413	-17	396

The acquisition-related expenses are reported in the Group Corporate/Other segment.

Reconciliation Q1-3/17


The table below shows the adjustments and the reconciliation from net income according to guidance, i.e. before acquisition-related expenses and before expenditures for further development of biosimilars business to net income according to IFRS.

-					
€m	Before acquisition-related expenses and before expenditures for further development of biosimilars business	Expenditures for further development of biosimilars business	Before acquisition- related expenses	Acquisition- related expenses	IFRS reported
Sales	25,191		25,191		25,191
EBIT	3,536	-14	3,522	-25	3,497
Net interest	-484		-484	-8	-492
Net income before taxes	3,052	-14	3,038	-33	3,005
Income taxes	-859	4	-855	7	-848
Net income	2,193	-10	2,183	-26	2,157
Noncontrolling interest	-854		-854		-854
Net income attributable to shareholders of					
Fresenius SE & Co. KGaA	1,339	-10	1,329	-26	1,303

Q1-3/17

The acquisition-related expenses are reported in the Group Corporate/Other segment.

Fresenius Group: Leverage Ratio




Before special items; pro forma acquisitions At annual average FX rates for both EBITDA and net debt

¹ Pro forma excluding advances made for the acquisition of hospitals from Rhön-Klinikum AG

² Pro forma acquisitions of Akorn, Inc. and Fresenius Kabi's biosimilars business; before acquisition-related expenses of ~€50 million; excluding further potential acquisitions

Fresenius Group Debt Maturity Profile¹



¹ September 30, 2017; based on utilization of major financing instruments

Update on Acquisitions

















Quirónsalud: Integration Status and Growth Prospects

Integration process

- Procurement analysis phase successfully completed; implementation phase commenced (e.g. lab disposables)
- Openness to learn from the best e.g. compare experience on medical practices

Growth prospects

- €50m greenfield investment project in Córdoba Andalusia on track:
 - 115 bed hospital provides state-of-the-art medical equipment and care
 - Opening expected for June 2018
- €31m hospital expansion in Pozuelo, Madrid
 - 2 additional operating theatres, 25 new examination rooms, 7 additional intensive care beds, new state-of-the-art MRI

Strong position

- PPP contracts in place up to 2041
- Four Quirónsalud hospitals ranked in Top 10 of Hospital Excellence Index (HEI)



Fresenius Kabi: Update on Acquisition Projects

AKORN

- FTC review: Disposal process fully on track
- Closing targeted for end of 2017
- Q3 performance below expectations
- Achievement of 2018 expectation challenging
- Strategic rationale unchanged: Deal offers offensive and defensive merits
- Pre-closing integration preparation progressing well

BIOSIMILARS

- Consolidated since 1st September 2017
- Product pipeline: All studies remain well on track
- Filing for Adalimumab imminent
- Regulatory environment further improving





Akorn: Transaction Highlights



Complementary product portfolio and pipeline diversifies Fresenius Kabi's IV generics offering





Access to additional distribution channels: retail, clinics and physicians



Adds growth potential in attractive adjacent segments such as ophthalmology and clinical dermatology



Substantial cost and growth synergies paired with limited integration complexity





Fully debt-financed



Accretive to Group net income¹ from 2018

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA; before integration costs




Akorn: Financially Sound Acquisition

for 100% of Akorn shares (US\$34/share)
\$\$130 m p.a.
p.a. before tax mid-term, ramp-up
before tax in total for 2018 - 2022
f € and US\$ debt instruments at ~4% p.a.
2018 (excluding integration costs), including integration costs)
· 2017

¹ Net Debt has been calculated based on the 10-Q filing of Akorn as per September 30, 2017 by deducting cash & cash equivalents (as reported) from long term debt (as reported) ² Net income attributable to shareholders of Fresenius SE & Co. KGaA

Akorn: Complementary Product Portfolio and Distribution Channels



Note: Sales mix based on 2016 data


Akorn: Diversified U.S. Portfolio

	Current Portfolio		Pipe	eline
		O AKORN		AKORN
Total Products	137	173	55	85
IV Analgesics & Anesthetics	•••	•	••	•
IV Anti-Infectives		•		••
IV Critical Care				
IV Oncolytics		•		•
Nutrition & IV Solutions	•	•		
Ophthalmics		•••		•••
Topicals		•		••
Orals				•
Nasal / Otics / Consumer Health		••		•
Animal Health		•		•

strong medium light

FRESENIUS

Akorn: Concentrated U.S. Footprint



Akorn: Detailed and Comprehensive Due Diligence

Process

- Bilateral exchange with Akorn since 11/2016
- Very comprehensive due diligence over more than two months covering all functional areas
- Virtual data room, management presentations and expert meetings
- Multiple visits of all manufacturing plants
- Detailed bottom-up business plan
- Internal resources supported by external advisers and specialists in new product areas

Addressed areas

- ANDA pipeline, related regulatory approvals and R&D costs
- New distribution channels and Akorn's strengths
- Sales practices, pricing history and related customer perception
- Competition in key product areas
- Plant status (technical and regulatory) and future manufacturing strategy
- Serialization readiness
- Accounting issues and internal control systems
- Current trading



As of April 2017

Biosimilars: Transaction Highlights



Strategic step to enhance Fresenius Kabi's position as a leading player in the injectable pharmaceuticals market



Direct access to attractive biosimilars development platform

Experienced team of biosimilars experts with excellent development know-how







Highly variable consideration strictly tied to development targets



EBITDA break-even in 2022



High triple-digit million sales from 2023 onwards



Biosimilars: Sound Risk/Reward Ratio

Purchase price	€156 m upfront payment	
Milestone payments	Up to €500 m, strictly tied to achievement of development targets	
Sales	First sales in 2019, ramp-up to high triple-digit € million from 2023 onwards	
Royalties	Single-digit percentage royalties based on sales	
EPS ¹	Significantly accretive from 2023 onwards	
Self-imposed investment ceiling	€1.4 bn incl. upfront and milestone payments as well as ramp-up of R&D and M&S expenses until EBITDA break-even in 2022	
Financing	Mainly free cash flow	
Closing	31 August 2017	

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA

Biosimilars: Highly Attractive Platform



Background: Established in 2012 as a Business Unit within the biopharmaceutical development/production network of Merck KGaA



Pipeline: Single-digit number of molecules in oncology and autoimmune diseases




Organization: Core team of >70 experts located in Aubonne and Vevey, Switzerland




Network: External partners supporting development, documentation and regulatory affairs

Merck Biopharma provides support in manufacturing (one production site reserved for biosimilars), analytics, regulatory, quality, safety and clinical operations.

Expanding U.S. Market Access



Who Brings What to a Great Party?



Financial Calendar / Contact

Financial Calendar

27 February 2018	Results FY 2017
3 May 2018	Results Q1/2018
18 May 2018	Annual General Meeting
31 July 2018	Results Q2/2018
30 October 2018	Results Q3/2018

Please note that these dates could be subject to change.

Contact

Investor Relations Fresenius SE & Co. KGaA phone: +49 6172 608-2485 e-mail: ir-fre@fresenius.com For further information and current news: <u>www.fresenius.com</u>

Follow us on Twitterwww.twitter.com/fresenius_irand LinkedIn:www.linkedin.com/company/fresenius-investor-relations